Menopause hormone therapy: latest developments and clinical practice
Menopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2019-01-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/menopause-hormone-therapy:-latest-developments-and-clinical-practice |
| _version_ | 1819024281830424576 |
|---|---|
| author | Tomas Fait |
| author_facet | Tomas Fait |
| author_sort | Tomas Fait |
| collection | DOAJ |
| description | Menopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its consequences. Systemic treatment may include estrogen, but an equally efficient alternative is tibolone. Nonhormonal therapy relies on phytoestrogens, black cohosh extract, and serotonin reuptake inhibitors. |
| first_indexed | 2024-12-21T04:52:18Z |
| format | Article |
| id | doaj.art-d78cca56498f47ae865dc409dd7bd303 |
| institution | Directory Open Access Journal |
| issn | 1740-4398 1740-4398 |
| language | English |
| last_indexed | 2024-12-21T04:52:18Z |
| publishDate | 2019-01-01 |
| publisher | BioExcel Publishing Ltd |
| record_format | Article |
| series | Drugs in Context |
| spelling | doaj.art-d78cca56498f47ae865dc409dd7bd3032022-12-21T19:15:24ZengBioExcel Publishing LtdDrugs in Context1740-43981740-43982019-01-0181910.7573/dic.212551Menopause hormone therapy: latest developments and clinical practiceTomas FaitMenopause hormone therapy (MHT) is the most efficient treatment for symptoms of acute climacteric syndrome and for efficient prevention of long-term estrogen deficiency. Vaginal administration of low doses of estrogen is a therapy of choice for treatment and prevention of urogenital atrophy and its consequences. Systemic treatment may include estrogen, but an equally efficient alternative is tibolone. Nonhormonal therapy relies on phytoestrogens, black cohosh extract, and serotonin reuptake inhibitors.https://www.drugsincontext.com/menopause-hormone-therapy:-latest-developments-and-clinical-practiceatrophic vaginitisbazedoxifeneclimacteric syndromemenopause hormone therapyphytoestrogenstibolone |
| spellingShingle | Tomas Fait Menopause hormone therapy: latest developments and clinical practice Drugs in Context atrophic vaginitis bazedoxifene climacteric syndrome menopause hormone therapy phytoestrogens tibolone |
| title | Menopause hormone therapy: latest developments and clinical practice |
| title_full | Menopause hormone therapy: latest developments and clinical practice |
| title_fullStr | Menopause hormone therapy: latest developments and clinical practice |
| title_full_unstemmed | Menopause hormone therapy: latest developments and clinical practice |
| title_short | Menopause hormone therapy: latest developments and clinical practice |
| title_sort | menopause hormone therapy latest developments and clinical practice |
| topic | atrophic vaginitis bazedoxifene climacteric syndrome menopause hormone therapy phytoestrogens tibolone |
| url | https://www.drugsincontext.com/menopause-hormone-therapy:-latest-developments-and-clinical-practice |
| work_keys_str_mv | AT tomasfait menopausehormonetherapylatestdevelopmentsandclinicalpractice |